Abstract
Traumatic brain injury, often referred to as the “silent epidemic,” is a nondegenerative, non-congenital insult to the brain due to a blow or penetrating object that disrupts the function of the brain leading to permanent or temporary impairment of cognition, physical and psychosocial functions. Traumatic brain injury usually has poor prognosis for long-term treatment and is a major cause of mortality and morbidity worldwide; approximately 10 million deaths and/or hospitalizations annually are directly related to traumatic brain injury. Traumatic brain injury involves primary and secondary insults. Primary injury occurs during the initial insult, and results from direct or indirect force applied to the physical structures of the brain. Secondary injury is characterized by longer-term degeneration of neurons, glial cells, and vascular tissues due to activation of several proteases, glutamate and pro-inflammatory cytokine secretion. In addition, there is growing evidence that the blood-brain barrier is involved in the course of traumatic brain injury pathophysiology and has detrimental effects on the overall pathology of brain trauma, as will be discussed in this work.
Keywords: Biomarkers, blood-brain barrier, brain injury, connexins, cytokines, inflammation, neuronal injury, traumatic brain injury.
CNS & Neurological Disorders - Drug Targets
Title:Traumatic Brain Injury and Blood-Brain Barrier Cross-Talk
Volume: 15 Issue: 9
Author(s): Mohammad Nasser, Fabienne Bejjani, Mohamad Raad, Hadi Abou-El-Hassan, Sarah Mantash, Amaly Nokkari, Naify Ramadan, Nouhad Kassem, Stefania Mondello, Eva Hamade, Hala Darwish, Kazem Zibara and Firas Kobeissy
Affiliation:
Keywords: Biomarkers, blood-brain barrier, brain injury, connexins, cytokines, inflammation, neuronal injury, traumatic brain injury.
Abstract: Traumatic brain injury, often referred to as the “silent epidemic,” is a nondegenerative, non-congenital insult to the brain due to a blow or penetrating object that disrupts the function of the brain leading to permanent or temporary impairment of cognition, physical and psychosocial functions. Traumatic brain injury usually has poor prognosis for long-term treatment and is a major cause of mortality and morbidity worldwide; approximately 10 million deaths and/or hospitalizations annually are directly related to traumatic brain injury. Traumatic brain injury involves primary and secondary insults. Primary injury occurs during the initial insult, and results from direct or indirect force applied to the physical structures of the brain. Secondary injury is characterized by longer-term degeneration of neurons, glial cells, and vascular tissues due to activation of several proteases, glutamate and pro-inflammatory cytokine secretion. In addition, there is growing evidence that the blood-brain barrier is involved in the course of traumatic brain injury pathophysiology and has detrimental effects on the overall pathology of brain trauma, as will be discussed in this work.
Export Options
About this article
Cite this article as:
Nasser Mohammad, Bejjani Fabienne, Raad Mohamad, Abou-El-Hassan Hadi, Mantash Sarah, Nokkari Amaly, Ramadan Naify, Kassem Nouhad, Mondello Stefania, Hamade Eva, Darwish Hala, Zibara Kazem and Kobeissy Firas, Traumatic Brain Injury and Blood-Brain Barrier Cross-Talk, CNS & Neurological Disorders - Drug Targets 2016; 15 (9) . https://dx.doi.org/10.2174/1871527315666160815093525
DOI https://dx.doi.org/10.2174/1871527315666160815093525 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin
CNS & Neurological Disorders - Drug Targets A Retrospective, Multi-Center Cohort Study Evaluating the Severity- Related Effects of Cerebrolysin Treatment on Clinical Outcomes in Traumatic Brain Injury
CNS & Neurological Disorders - Drug Targets Proteomic Analysis of Neutrophil Priming by PAF
Protein & Peptide Letters Editorial [Hot Topic: Regulation of Brain Functions by Adenosine A2A Receptors:Implication for Therapeutics (Executive Editor: Patrizia Popoli) ]
Current Pharmaceutical Design Editorial (Thematic Issue: New Therapeutic Targets in Clinical Medicine)
Current Pharmaceutical Design Cardiac Amyloidosis Responding to Bortezomib: Case Report and Review of Literature
Current Cardiology Reviews A Diabetes Treatment Strategy to Reduce the Risk of Cardiovascular Events: Clinical Benefits and Potential of Linagliptin
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Small Peptide and Protein-based Molecular Probes for Imaging Neurological Diseases
Current Protein & Peptide Science Ethanolamine: A Potential Promoiety with Additional Effects on the Brain
CNS & Neurological Disorders - Drug Targets The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia
Current Pharmaceutical Design Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract
Current Pharmaceutical Design Exploring the Role of Gene Therapy for Neurological Disorders
Current Gene Therapy Immunotherapeutic Approaches in MS: Update on Pathophysiology and Emerging Agents or Strategies 2006
Endocrine, Metabolic & Immune Disorders - Drug Targets Clinical Applications of Choline PET/CT in Brain Tumors
Current Pharmaceutical Design Mechanisms of Melatonin in Alleviating Alzheimer’s Disease
Current Neuropharmacology Molecular and Biochemical Features in Alzheimers Disease
Current Pharmaceutical Design Overlap between ADHD and Autism - Clinical and Genetic Evidence
Current Psychiatry Reviews Scope and Applications of Nanomedicines for the Management of Multiple Sclerosis
Current Drug Metabolism COVID-19: Our Current Knowledge of Epidemiology, Pathology, Therapeutic Approaches, and Diagnostic Methods
Anti-Cancer Agents in Medicinal Chemistry Strategies to Tackle Early Low Flow States in the Extremely Preterm Infant
Current Pediatric Reviews